NO20043549L - Anvendelse av benzotiazepiner som har aktivitet som inhibitorer av tynntarm-gallesyretransport for a redusere kolesterolemi - Google Patents

Anvendelse av benzotiazepiner som har aktivitet som inhibitorer av tynntarm-gallesyretransport for a redusere kolesterolemi

Info

Publication number
NO20043549L
NO20043549L NO20043549A NO20043549A NO20043549L NO 20043549 L NO20043549 L NO 20043549L NO 20043549 A NO20043549 A NO 20043549A NO 20043549 A NO20043549 A NO 20043549A NO 20043549 L NO20043549 L NO 20043549L
Authority
NO
Norway
Prior art keywords
benzothiazepines
inhibitors
activity
bile acid
small intestinal
Prior art date
Application number
NO20043549A
Other languages
English (en)
Norwegian (no)
Inventor
Ann-Margret Lindqvist
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO20043549L publication Critical patent/NO20043549L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20043549A 2002-01-26 2004-08-25 Anvendelse av benzotiazepiner som har aktivitet som inhibitorer av tynntarm-gallesyretransport for a redusere kolesterolemi NO20043549L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0201850.5A GB0201850D0 (en) 2002-01-26 2002-01-26 Therapeutic treatment
PCT/GB2003/000350 WO2003061663A1 (fr) 2002-01-26 2003-01-23 Utilisation de benzothiazepines ayant une activite inhibitrice du transport de l'acide biliaire ileal pour reduire la cholesterololemie

Publications (1)

Publication Number Publication Date
NO20043549L true NO20043549L (no) 2004-08-25

Family

ID=9929835

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043549A NO20043549L (no) 2002-01-26 2004-08-25 Anvendelse av benzotiazepiner som har aktivitet som inhibitorer av tynntarm-gallesyretransport for a redusere kolesterolemi

Country Status (17)

Country Link
US (1) US20050124557A1 (fr)
EP (1) EP1478368A1 (fr)
JP (1) JP2005523255A (fr)
KR (1) KR20040079949A (fr)
CN (1) CN1617729A (fr)
BR (1) BR0307093A (fr)
CA (1) CA2473721A1 (fr)
GB (1) GB0201850D0 (fr)
HU (1) HUP0500009A3 (fr)
IS (1) IS7357A (fr)
MX (1) MXPA04007201A (fr)
NO (1) NO20043549L (fr)
PL (1) PL371521A1 (fr)
RU (1) RU2004126148A (fr)
TW (1) TW200302089A (fr)
WO (1) WO2003061663A1 (fr)
ZA (1) ZA200405866B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
MY131995A (en) 2001-09-08 2007-09-28 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) * 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
KR20060056944A (ko) 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
EP2367554A4 (fr) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Inhibiteurs de recyclage de l'acide biliaire pour le traitement de l'obésité et du diabète
EP4137137A1 (fr) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Inhibiteurs et satiogènes de recyclage d'acide biliaire pour le traitement du diabète, de l'obésité et d'états gastro-intestinaux inflammatoires
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
MX366925B (es) * 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
MY176863A (en) * 2010-11-08 2020-08-24 Albireo Ab Ibat inhibitors for treatment of metabolic disorders and related conditions
US20120114588A1 (en) * 2010-11-08 2012-05-10 Albireo Ab Ibat inhibitors for treatment of metabolic disorders and related conditions
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (fr) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Preparation solide et procede d'inhibition ou d'attenuation de coloration de celle-ci
EP3012252A1 (fr) 2014-10-24 2016-04-27 Ferring BV Formes crystallines d'Elobixibat
CA3002540C (fr) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Utilisation de (r)-2-(7-(4-cyclopentyl-3(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acide acetique pour le traitement de conditions liees au recepteur s1p1
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
CA3011595C (fr) 2016-02-09 2024-01-02 Albireo Ab Pastilles de cholestyramine et procedes de preparation associes
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JP7328207B2 (ja) 2017-08-09 2023-08-16 アルビレオ・アクチボラグ コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法
KR20210024033A (ko) 2018-06-20 2021-03-04 알비레오 에이비 오데빅시바트의 약학 제제
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
SG11202108566VA (en) 2019-02-06 2021-09-29 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN113453753B (zh) 2019-02-06 2024-07-23 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
JP7665621B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2021110885A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composés de benzothiadiazépine et leur utilisation en tant que modulateurs de l'acide biliaire
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3158181A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composes de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire
CA3158195A1 (fr) 2019-12-04 2021-06-10 Per-Goran Gillberg Composes de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
CN117412955A (zh) 2021-06-03 2024-01-16 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN119053330A (zh) 2022-04-22 2024-11-29 阿尔比里奥公司 皮下给药asbt抑制剂
EP4536232A1 (fr) 2022-06-09 2025-04-16 Albireo AB Traitement de l'hépatite
CN119487013A (zh) 2022-07-05 2025-02-18 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
EP4629997A1 (fr) 2022-12-09 2025-10-15 Albireo AB Inhibiteurs d'asbt dans le traitement de maladies rénales
WO2025146508A1 (fr) 2024-01-05 2025-07-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs d'acide biliaire
WO2025146507A1 (fr) 2024-01-05 2025-07-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs d'acide biliaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900757A (en) * 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
ATE242258T1 (de) * 1997-03-14 2003-06-15 Aventis Pharma Gmbh Hypolipidemische 1,4-benzothiazepin-1,1-dioxide
SE0000772D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
HUP0500009A3 (en) 2006-05-29
PL371521A1 (en) 2005-06-27
CA2473721A1 (fr) 2003-07-31
GB0201850D0 (en) 2002-03-13
WO2003061663A1 (fr) 2003-07-31
EP1478368A1 (fr) 2004-11-24
TW200302089A (en) 2003-08-01
RU2004126148A (ru) 2005-05-27
CN1617729A (zh) 2005-05-18
IS7357A (is) 2004-07-21
JP2005523255A (ja) 2005-08-04
ZA200405866B (en) 2006-07-26
BR0307093A (pt) 2004-12-28
MXPA04007201A (es) 2004-11-26
KR20040079949A (ko) 2004-09-16
US20050124557A1 (en) 2005-06-09
HUP0500009A2 (hu) 2005-04-28

Similar Documents

Publication Publication Date Title
HUP0500009A3 (en) Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia
AU2003249549A1 (en) Generalized metronome for modification of biorhythmic activity
IL214281A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
NO20054880D0 (no) Azaspiroalkanderivater som inhibitorer av metallproeaser
DK1660431T3 (da) Phenoxyeddikesyrederivater
DK2178840T3 (da) Azabiphenylaminobenzoesyre-derivater som dhodh-hæmmere
DK1633748T3 (da) Quinolinfrtibsyrt dom phosphodiesteraseinhibitorer
DK2121614T3 (da) Aminonikotin og isonikotinsyrederivater som dhodh-inhibitorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
NO20043793L (no) Nikotinamidderivater anvendelige som PDE4 inhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
ATE419250T1 (de) 2-cyanopyrrolidincarbonsäureamide als dipeptidylpeptidase-iv-inhibitoren
ZA200705075B (en) Novel hydantoin derivatives as metalloproteinase inhibitors
WO2006099468A3 (fr) Procede de purification de la duloxetine hydrochloride
PL379385A1 (pl) Nowe związki 2-pirydynyloetylobenzamidowe
DK1740569T3 (da) Imidazol-derivater som TAFla-inhibitorer
IL164645A0 (en) Polymorph of 4-Ä2-Ä1-(2-ethoxyethyl)-1H-benzidimazole-2-YLÜ-1-piperidinylÜethylÜ-??-dimethyl-benzenoacetic acid
EP1765761A4 (fr) Nouveaux analogues de 3-o-acetyl-11-ceto-beta-acide boswellique
EP1831196A4 (fr) Derives d'hydantoine en tant qu'inhibiteurs de metalloproteinase
IS7808A (is) Aðferð til nýmyndunar í iðnaði á metýldíester 5-amínó-3-karboxýmetýl-4-sýanó-2-þíófenkarboxýlsýru
DK1856063T3 (da) 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme
PT1513806E (pt) Sais de ácido sulfónico de derivados do ácido mandélico
IL164267A0 (en) Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
CR8046A (es) Novedosos compuestos de acido fosfonico como inhibidores de la serina proteasa

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application